Filing identity and reporting period
The supplied filing is Sigma Labs, Inc.’s Form 10-Q for the quarter ended March 31, 2013—not a filing for Nexttrip, Inc. Verify the issuer before relying on this summary. Sigma Labs develops manufacturing-quality and advanced-materials technologies and also earns consulting revenue. Its technology products were not yet generating sales.
Financial performance and liquidity
- Revenue: $164,264, up 91% from $86,092 in Q1 2012; primarily consulting services.
- Gross profit and margin: $77,334 and 47.1%, versus $276 and 0.3% a year earlier.
- Expenses: General and administrative $135,551 (up from $131,434); payroll $88,409 (down from $123,490); noncash stock compensation $50,000 (versus none).
- Net loss: $196,616, improved from $254,737. Basic and diluted loss per share was reported as $0.00, rounded.
- Cash flow: Operating activities provided $44,410, compared with $136,765 used in Q1 2012. The 2013 inflow included a $180,433 reduction in accounts receivable. No investing cash flow or financing proceeds were reported for the quarter.
- Liquidity: Cash was $194,481 at March 31, versus $150,071 at December 31. Working capital was $196,481, down from $315,574; current assets were $302,888 and current liabilities $106,407.
- Debt and equity: No borrowings are shown on the balance sheet; liabilities consist of accounts payable and accrued expenses. The company said it had no credit facility. Stockholders’ equity was $411,154, down from $557,770.
Material changes and notable items
Revenue and gross profit increased substantially year over year, while the net loss narrowed. Lower payroll expense and improved gross profit contributed to the improvement; $50,000 of stock compensation was recorded in the quarter. The company issued 4.25 million shares to consultants during the quarter, of which 2,583,333 were unvested at quarter-end, adding dilution and deferred compensation. The filing also reports 500,000 unvested shares cancelled.
At March 31, 2013, the balance sheet reports 432,917,400 shares issued and 426,834,067 outstanding. The cover page reports 432,917,400 issued and 428,917,400 outstanding as of May 2. These figures differ and merit verification.
Outlook, risks, and contingencies
Management expected to pursue commercialization of IPQA and other technologies during 2013, including applications in additive manufacturing and biomedical prosthetics. It anticipated slightly higher general and administrative costs and increased payroll and noncash compensation as operations and marketing expanded. These are expectations, not reported results; the filing does not provide formal financial guidance.
As of May 15, management cited one active B6 Sigma consulting contract expected to generate up to $252,862 by the third quarter and four Sumner contracts expected to generate up to $250,000 during the rest of 2013. These amounts are prospective contract estimates, not recognized revenue. Management said it expected available funds and consulting receipts to cover operating needs for the balance of 2013, but also stated that funding depends on consulting work and securities sales until technology revenues become significant. The going-concern note says the company has sustained losses, may need additional capital, and has no assurance it can raise funds or achieve profitability.
Fixed-price consulting contracts carry cost-estimation and execution risk: cost overruns could reduce or eliminate profit. The company reported no off-balance-sheet arrangements and no legal proceedings. A May 2013 consulting agreement provided 500,000 restricted shares for marketing services; this was subsequent to quarter-end.
Important facts for investors to verify
- Confirm that Sigma Labs, Inc., rather than Nexttrip, Inc., is the intended issuer and filing.
- Reconcile the quarter-end and May 2 common-share counts and assess dilution from consultant and incentive-plan shares.
- Assess whether the cited consulting contracts were performed, collected, and profitable, particularly fixed-price engagements.
- Verify commercialization progress and whether technology licensing or product sales are producing material revenue.
- Evaluate liquidity and financing needs against the going-concern disclosure; the filing provides no committed credit or third-party capital.